attention-deficit drugs | editorial

Quota system breaks down

A NATIONWIDE shortage of medicines for attention-deficit hyperactivity disorder is causing undue stress to those with the ailment - or, more often, their parents. Individuals looking to refill prescriptions have to drive from pharmacy to pharmacy in search of hidden stockpiles of medicines like Ritalin, Adderall, and their generic counterparts.

As a result, patients are asking tough questions of the pharmaceutical industry and of government regulators. The Drug Enforcement Administration has shouldered much of the blame, since the agency limits how much of the amphetamine salts - the drugs’ active ingredients - can be distributed to manufacturers each year. That ire isn’t entirely justified: The DEA regulates amphetamines to prevent overflows from falling into the hands of their abusers - a large and growing population, especially among college students. The DEA also points out that the quota it set for pharmaceutical amphetamines last year was never depleted.

Your comment is subject to the rules of our Posting Policy

This comment may appear on your public profile. Public Profile FAQ